View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 6, 2021

AstraZeneca seeks EUA for antibody combination to prevent Covid-19

The EUA request entails data from the PROVENT Phase III trial, STORM CHASER Phase III and the Phase I trials.

AstraZeneca has submitted a request seeking the US Food and Drug Administration’s (FDA) emergency use authorization (EUA) for its long-acting antibody (LAAB) combination, AZD7442, to prevent symptomatic Covid-19.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Discovered by Vanderbilt University Medical Center, AZD7442 is a combination of tixagevimab (AZD8895) and cilgavimab (AZD1061).

In June last year, it was licenced to AstraZeneca.

The request filing made for the EUA includes data from the PROVENT Phase III pre-exposure prophylaxis trial which included 5,197 participants in a 2:1 randomisation AZD7442 to placebo.

It showed a 77% reduction in risk of developing symptomatic Covid-19 using AZD7442.

According to the preliminary ‘in vitro’ findings, the long-acting antibody combination demonstrated broad anti-Covid activity and neutralised SARS-CoV-2 viral variants, including the Delta and Mu that emerged recently.

Subjects with co-morbidities and in need of additional protection from SARS-CoV-2 infection were included in the trial.

The EUA request filing also includes safety and efficacy data from the STORM CHASER Phase III trials and the Phase I trial.

AstraZeneca stated that its YTE half-life extension technology, which triples its strength when compared to conventional antibodies, was used to optimise AZD7442.

If the product is approved in the US, it would be the first LAAB to get the EUA for Covid-19 prevention.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing Covid-19.

“With this first global regulatory filing, we are one step closer to providing an additional option to help protect against Covid-19 alongside vaccines. We look forward to sharing AZD7442 data for the treatment of Covid-19 later this year.”

The company is also carrying out discussions with the US and other governments globally about supply agreements for AZD7442.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology